types of cancer (6, 7), including breast cancer (8, 9). However, how TAMs impact on 3 the malignant progression of phyllodes tumor and whether TAMs density can be a 4 prognostic factor for phyllodes tumors are still unknown.
5
Macrophages are usually found in close proximity with collagen-producing 6 myofibroblasts (9) . Macrophages produce profibrotic mediators that directly activate 7 fibroblasts, including transforming growth factor (TGF)-β1 and platelet-derived 8 growth factor (PDGF) (10). Macrophages also provide insulin-like growth factor-1, 9 which stimulates the proliferation and survival of myofibroblasts and promotes 10 collagen synthesis by these cells (11) . In this study, we found that TAMs are essential PTs cells were isolated from benign and malignant PTs as previously described (4).
7
TAMs were isolated from eight fresh breast malignant PTs samples as previously 8 described (12, 13), with slight modifications. Briefly, the tissues were minced into 9 small (1 to 2 mm) pieces and digested with 5% fetal bovine serum Dulbecco's 10 modified Eagle's medium containing 2 mg/ml collagenase I and 2 mg/ml 11 hyaluronidase (Sigma) at 37°C for 2 hr. The cells were sequentially filtered through 12 500 μm mesh, 100 μm, and 70 μm cell strainer. The cells were then centrifuged in a
13
Beckman Allegra X-15R centrifuge at 2,500 rpm for 20 min with 1 ml cell suspension 14 above 5ml 45% Percoll (GE Healthcare) in the middle and 5ml 60% Percoll at the 15 bottom in a 15 ml tube. Mononuclear cells were collected from the cell layer in the 16 interphase between 45% and 60% Percoll. CD14+ monocytes and macrophages were 17 isolated by a magnetic-activated cell sorting using direct CD14 Isolation Kit (Miltenyi 
Animal Experiments

10
All animal work was conducted in accordance with a protocol approved by the 
Results
16
TAMs density is associated with malignant progression of PT and CCL18 is an 17 independent prognostic marker for PT patients 18 Evidence from clinical and epidemiological studies has shown a strong correlation 19 between TAMs density and poor prognosis in several types of cancer (6, 7 malignant PTs is significantly higher than that in benign and borderline PTs (Fig. 1A) .
4
Previously, we have found PITPNM3 was the receptor of CCL18 on the surface of 5 breast tumor cells (12). CCR8 was also reported as the CCL18 receptor (14). We then 6 examined the level of PITPNM3 or CCR8 in PTs and found that PIPTNM3 was 7 increased in malignant PTs (Fig. 1A) , whereas CCR8 was not ( Supplementary Fig.   8 S1A). CCL18 is expressed in both TAMs and DCs (14). To confirm whether CCL18 9 positive cells were macrophages, two macrophages markers CD68 and CD163 were 10 used. CD68 is specially expressed by macrophages as well as in tolerogenic DCs (15).
11
CD163 is a marker of M2 macrophages. Microscopy revealed that both CD68 Furthermore, we measured the CCL18 mRNA levels in fresh frozen PT tissues and 16 primary PT cells isolated from benign, borderline or malignant PTs, using normal 17 breast tissues as a control. Using qRT-PCR, we found that the mRNA levels of CCL18 18 from fresh frozen tissues were progressively increased from normal breast tissue to 19 benign, borderline and malignant PTs (Fig. 1C) extremely high levels of CCL18 mRNA ( Supplementary Fig. S1C ). ELISA assay was 1 used to measure the serum CCL18 level of PT patients or the secreted CCL18 level in 2 the culture suspension of primary cells isolated from PT tumors. We found that the 3 CCL18 protein levels in the serum of patients with malignant PTs were significantly 4 higher than in those with benign and borderline PTs (Fig. 1D) Fig. S1D ). Together, these results indicate that TAMs density is associated with the 9 malignant progression of PTs and CCL18 is mostly produced by TAMs.
10
Next, we tested whether CCL18 had clinical prognostic value for PT patients. The 11 268 PT patients were followed up for 8-148 months (median follow-up time is 112 12 months). During the follow-up, 49 cases were diagnosed with recurrence, including 13 18 in the benign group, 9 in the borderline group and 22 in the malignant group. 14 Additionally, 31 cases were diagnosed with metastasis, with 3 in the borderline group 15 and 28 in the malignant group.
16
We then analyzed the association of CCL18 expression with the clinicopathological Table S1 ). The expression of CCL18 increased with 18 higher tumor grade, mitotic activity and stromal overgrowth (p<0.001), but was not Table S1 Fig. S1E and F) . In addition, Table S2 ). These 9 results suggest that the TAMs density is associated with malignant progression of PT, 10 and the levels of CCL18 can be used to predict the outcome of PT patients. (9), and there is strong evidence that this interaction is reciprocal (16).
Macrophages produce profibrotic mediators that directly activate fibroblasts, that of CCL18 producing cells in the 268 PT samples (Fig. 4A, r=0 .752, p<0.001). of NF-κB in CCL18-induced miR-21 expression, the luciferase reporter assay was 5 applied in PT cells. We found that NF-κB activity was escalated to a 6.2-fold increase 6 in CCL18 treated cells. The TNF-α-treated PT cells were used as positive control (Fig   7   4C ). Constantly, we revealed that CCL18-induced p65 nuclear translocation could be 8 reversed by both NF-κB pathway inhibitors and siPITPNM3, suggesting CCL18 9 induced activation of NF-κB pathway through membrane-associated 10 phosphatidylinositol transfer protein 3 (PITPNM3) ( Supplementary Fig. S3A and B).
11
The PITPNM3 RNAi efficiency was detected by western blot ( Supplementary Fig.   12 3C). Again, we confirmed that CCL18 promoted NF-κB pathway via PITPNM3, as Fig.S3D ).Additionally, CCL18 upregulated the mRNA levels 15 of several NF-κB target genes, including IL8, IL4, Twist, etc (Fig 4D) . Collectively, 16 these data suggest that CCL18 can enhance NF-κB transcriptional activity in PT cells.
17
To investigate whether NF-κB can directly regulate miR-21 expression, inhibitors (Fig. 4F) . We next examined the functional relationships among CCL18, NF-κB and 4 miR-21 in breast PT cells. When PT cells were treated by CCL18 for 24 hours, 5 miR-21 promoter activity was increased by 8.6-fold (Fig. 4G) . Taken together, our 6 results indicate that CCL18 upregulates miR-21 expression via activating NF-κB. for 48 hours and then exposed to 20ng/ml CCL18 or co-cultured with TAMs for 48 14 hours. We found that CCL18 treatment increased the mRNA (Fig. 5A and C) and 15 protein level of α-SMA (Fig. 5 B and D) . However, the NF-κB inhibitor BAY-117082 
21
5E and Supplementary Fig. S4A ). We then evaluated the effect of NF-κB and miR-21 
on the invasive ability of PT cells treated with CCL18 or cocultured with TAMs.
1
Consistent with previous results, BAY, JSH and miR-21 ASO also abrogated the 2 CCL18 or TAMs-promoted migration, invasion (Fig. 5E and Supplementary Fig. S4B)   3 and proliferation ( Fig. 5F and Supplementary Fig. S4C) 
that PTEN level decreased and p-AKT increased from benign to malignant PTs (Fig.   1   6C) . Together, these data suggested that TAMs induced myofibroblast differentiation 2 and promoted PT tumorigenecity through secreting CCL18 to activate PI3K-AKT 3 pathway via NF-κB/miR-21/PTEN axis (Fig. 6D) . We also explored which factor in 4 the microenvironment promoted macrophages producing CCL18. We compared the 5 cytokine expressed by the PT cells and found that hepatocyte growth factor (HGF) Fig.S5C ). Fig. 7A and B) . These data suggest that CCL18 play an 4 important role in the malignant transformation of breast PTs.
5
To further evaluate whether CCL18 regulates myofibroblast differentiation in vivo, 6 we examined the protein levels of α-SMA, PTEN, p-Akt and Ki67 in the xenografts 7 using immunohistochemistry (Fig. 7C) . Similar to the results obtained in vitro, hypoxanthine-guanine-phos-phoribosyltransferase (HPRT) mRNA in the livers (Fig.   20 7D, E and G). However, there was no significant lung metastasis observed in the mice 21 according to histological examination (data not shown), wet weight of lung ( and human HPRT mRNA level (Fig. 7G) . In addition to the M2 polarization of (Fig 6D) . Our previous data and the present study have 17 demonstrated that CCL18 and miR21 play major roles in myofibroblast transition of 18 PTs, suggesting that the above intercellular communication pathway from TAM to 19 myofibroblast may serve as a major driver of tumorigenicity in phyllodes tumors.
20
Even with surgical resection, local recurrence rate of PTs is still as high as 8% to 36% shows CCL18 is co-localized with CD163, the marker of M2 macrophages. Anti-CD163 antibody is labeled as red, Anti-CCL18 antibody is labeled as green. Cell 7 nuclei are counterstained with DAPI (blue). Scale bar, 20μm. 
